Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy [4]

Gut

Volumn 55, Issue 8, 2006, Pages 1208-1209

  Idilman, R ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE;

CANCER; CANCER CHEMOTHERAPY; DRUG TOLERABILITY; HEPATITIS B; HUMAN; LETTER; PRIORITY JOURNAL; VIRUS REACTIVATION;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; HEMATOLOGIC NEOPLASMS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; VIRUS ACTIVATION;

EID: 33746134144     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (7)

1. Hoofnagle JH, Dusheiko GM, Schafer DF, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982;96:447-9.
2. Yeo W, Chan PKS, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy. J Med Virol 2000;62:299-307.
3. Rossi G, Pelizzari A, Motta M, et al. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001;115:58-62.
4. Shibolet O, Ilan Y, Gillis S, et al. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002;100:391-6.
5. Idilman R, Arat M, Soydan E, et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Virol Hepatitis 2004;11:141-7.
6. Papatheodoridis GV, Dimou E, Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: Antiviral efficacy and viral resistance. Am J Gastroenterol 2002;97:1618-28.
7. Idilman R. Lamivudine prophylaxis in HBV carriers with hemato-oncological malignancies who receive chemotherapy. J Antimicrob Chemother 2005;55:828-31.